Previous 10 | Next 10 |
Clinical-stage biotechnology company ContraFect ( NASDAQ: CFRX ) is set to purchase ~$7M of its common stock. The company has entered into a securities purchase agreement with a single institutional investor for the purchase. CFRX has agreed to issue 4,350,000 shares and and ...
YONKERS, N.Y., Dec. 13, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of ...
Looking For Cheap Stocks To Buy For Under $1? Check Out Penny Stocks It might seem evident that penny stocks include shares of companies trading for prices below $0.99. But according to the broader definition, the term includes other stocks that trade for less than $5. Whichever definition yo...
YONKERS, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatme...
Contrafect press release ( NASDAQ: CFRX ): Q2 GAAP EPS of -$0.43 misses by $0.20 . As of September 30, 2022, ContraFect had cash, cash equivalents and marketable securities of $17.6 million. For further details see: Contrafect GAAP EPS of -$0.43 misses by $0....
YONKERS, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the tre...
YONKERS, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatm...
YONKERS, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatm...
Contrafect press release ( NASDAQ: CFRX ): Q2 GAAP EPS of -$0.46 misses by $0.13 . As of June 30, 2022, ContraFect had cash, cash equivalents and marketable securities of $27.3 million. Shares +4% PM For further details see: Contrafect GAAP EPS of -$0...
YONKERS, N.Y., Aug. 15, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the tre...
News, Short Squeeze, Breakout and More Instantly...
ContraFect Corporation Company Name:
CFRX Stock Symbol:
NASDAQ Market:
ContraFect Corporation Website:
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
ContraFect Corporation (CFRX) is expected to report $-0.66 for Q3 2023